CA
NZ
UK
AU
IND
US
A Form 4 filed with the SEC on August 4, 2026, discloses that John R. Linker, Executive Vice President of Finance and CFO of Columbus McKinnon Corp (NASDAQ: CMCO), purchased 7,500 shares of common stock on July 31, 2026.
A Form 4 filed with the SEC on August 4, 2026, discloses that John A. Seaman III, Executive Vice President and Chief Credit Officer of C & F Financial Corp (NASDAQ: CFFI), sold 650 shares of common stock on August 3, 2026.
Morgan Stanley Finance LLC filed Preliminary Pricing Supplement No. 17,906 on August 4, 2026, under Rule 424(b)(2), offering Contingent Income Auto-Callable Securities with Daily Trigger Monitoring due February 16, 2028, linked to the worst performing of the S&P 500 Index, the Russell 2000 Index, …
David E. Rainbolt, a director and 10% owner of BancFirst Corp /OK/ (NASDAQ: BANF), filed a Form 4 on August 4, 2026, disclosing a sale of 11,497 shares of common stock on August 3, 2026.
Denise M. Faltischek, Chief Strategy Officer of Tilray Brands, Inc. (NASDAQ: TLRY), filed a Form 4 on August 4, 2026, disclosing an open-market purchase of common stock on August 3, 2026.
Aaron Samuel Greenberg, Chief Strategy Officer of Nayax Ltd. (NASDAQ: NYAX), filed a statement of changes in beneficial ownership on August 4, 2026, reporting the sale of ordinary shares on August 3, 2026, in connection with the vesting of restricted share units.
Morgan Stanley Finance LLC filed Pricing Supplement No. 17,475 on July 31, 2026, under Rule 424(b)(2), detailing the terms of market-linked, auto-callable principal-at-risk securities due August 3, 2029, linked to the lowest performing of Broadcom Inc., Micron Technology, Inc., and Pfizer Inc. common stock, …
Morgan Stanley Finance LLC filed a preliminary pricing supplement (No. 17,902) on August 4, 2026, under Rule 424(b)(2), offering six-year structured notes linked to the EURO STOXX 50 Index and maturing August 12, 2032.
Chen David Lifeng, a director of VNET Group, Inc. (NASDAQ: VNET), filed a Form 4 on August 4, 2026, disclosing the vesting of restricted share units and the resulting acquisition of Class A ordinary shares on July 31, 2026.
AbbVie Inc. filed a preliminary prospectus supplement (Form 424B5) on August 4, 2026, disclosing a multi-tranche senior note offering consisting of one floating rate series and eight fixed rate series, with proceeds intended primarily to fund the acquisition of Apogee Therapeutics, Inc.
Please wait processing your request...